2.Hemorrhagic Cystitis due to Intravesical Instillation of Gentian Violet Completely Recovered with Conservative Therapy.
Se Joong KIM ; Dong Hee KOH ; Jung Seun PARK ; Hyun Soo AHN ; Jong Bo CHOI ; Young Soo KIM
Yonsei Medical Journal 2003;44(1):163-165
Chemical cystitis due to intravesical instillation of gentian violet or crystal violet is rare and all of the reported cases have been in adults using undiluted solution, which resulted in long-term sequelae. This is a case report on a 16-month-old boy with hemorrhagic cystitis after the instillation of diluted gentian violet into the bladder to rule out bladder injury during inguinal herniorrhaphy. Although he was completely recovered with conservative therapy, gentian violet, even when diluted, should not be used on the urinary tract.
Administration, Intravesical
;
Bladder Diseases/*chemically induced/*therapy
;
Cystitis/*chemically induced/*therapy
;
Gentian Violet/*administration & dosage/*adverse effects
;
Hemorrhage/*chemically induced/*therapy
;
Human
;
Infant
;
Male
3.Adverse events related to bevacizumab and the management principles in non-small cell lung cancer.
Chinese Journal of Lung Cancer 2010;13(6):563-567
Angiogenesis Inhibitors
;
adverse effects
;
Antibodies, Monoclonal
;
adverse effects
;
Antibodies, Monoclonal, Humanized
;
Bevacizumab
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
Hemorrhage
;
chemically induced
;
Humans
;
Hypertension
;
chemically induced
;
Lung Neoplasms
;
drug therapy
;
Proteinuria
;
chemically induced
;
Thromboembolism
;
chemically induced
4.Penicillin G-induced hemorrhagic cystitis.
The Korean Journal of Internal Medicine 2015;30(5):742-742
5.Risk analysis for aspirin and postoperative intracranial hemorrhage--report of 3 cases.
Shu-qing YU ; Ji-sheng WANG ; Nan JI ; Wei LIU ; Ke QIAN
Chinese Medical Journal 2009;122(10):1231-1233
6.Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment.
Chinese Journal of Oncology 2010;32(7):481-486
Angiogenesis Inhibitors
;
adverse effects
;
therapeutic use
;
Angiotensin-Converting Enzyme Inhibitors
;
therapeutic use
;
Antibodies, Monoclonal
;
adverse effects
;
therapeutic use
;
Antibodies, Monoclonal, Humanized
;
Aspirin
;
administration & dosage
;
therapeutic use
;
Bevacizumab
;
Hemorrhage
;
chemically induced
;
Humans
;
Hypertension
;
chemically induced
;
drug therapy
;
Intestinal Perforation
;
chemically induced
;
surgery
;
Neoplasms
;
drug therapy
;
Proteinuria
;
chemically induced
;
Thromboembolism
;
chemically induced
;
drug therapy
7.The Effect of Non-steroidal Anti-inflammatory Drugs in Upper Gastrointestinal Bleeding.
Sang Woo LEE ; Hak Yang KIM ; Soo Heon PARK ; Ki Baik HAHM ; Jong Myon BAE ; Hyun Chae JUNG ; Jin Ho KIM
The Korean Journal of Gastroenterology 2004;44(1):13-18
BACKGROUND/AIMS: To evaluate the association between non-steroidal anti-inflammatory drugs (NSAIDs) use and upper gastrointestinal (UGI) bleeding, we performed a case-control study at the six University affiliated hospitals for one year. METHODS: Case and control subjects matched for age and sex were selected by endoscopy. Subjects were asked for the use of NSAIDs, past medical history, history of other medications, and smoking. The age and sex adjusted risk for UGI bleeding with NSAIDs use was compared between the case and control groups. RESULTS: The odd ratios of UGI bleeding with NSAIDs intake adjusted for past medical and medication history, past medical history only, and medication history only were 5.0, 5.0, and 1.7, respectively. The cases had significantly more history of NSAIDs intake, more diseases in medical history, and more medications other than NSAIDs compared to the controls. There was no relationship between UGI bleeding and concomitant medications in the both groups. CONCLUSIONS: This multicenter study suggests that a history of NSAIDs intake is strongly associated with UGI bleeding in Korea.
Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
;
Case-Control Studies
;
English Abstract
;
Gastrointestinal Hemorrhage/*chemically induced
;
Humans
9.A case of bromadiolone poisoning leading to digestive tract, abdominal hemorrhage and secondary paralytic ileus.
Hong Fan CHEN ; Zhi Jian ZHANG ; Cheng Jin YOU ; Li CHEN
Chinese Journal of Industrial Hygiene and Occupational Diseases 2022;40(9):707-709
Bromadiolone, commonly known as super warfarin, is a long-acting coumarin dicoumarin rodenticide. The mechanism of bromadiolone is mainly to inhibit vitamin K1 epoxide reductase and affect the synthesis of coagulation factors Ⅱ, Ⅶ, Ⅸ and Ⅹ, which causes blood coagulation dysfunction and systemic multiple organ hemorrhage. Here, we report of a case of bromadiolone poisoning patient who had digestive tract, abdominal hemorrhage, as well as secondary paralytic ileus. After blood product transfusion and vitamin K1 supplementation, the patient was discharged after the physical condition was improved. It's suggestied that clinicians should pay attention to rare complications to prevent missed diagnosis when treating other bromadiolone poisoning.
4-Hydroxycoumarins
;
Blood Coagulation Factors
;
Dicumarol
;
Hemorrhage
;
Humans
;
Intestinal Pseudo-Obstruction/chemically induced*
;
Oxidoreductases
;
Rodenticides
;
Vitamin K 1
;
Warfarin
10.Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials.
De-Jie FU ; Cheng CHEN ; Lin GUO ; Liu YANG
Chinese Journal of Traumatology 2013;16(2):67-76
OBJECTIVEThe effect of tranexamic acid (TA) on patients receiving total knee arthroplasty (TKA) has been reported in many small clinical trials. But single trials are not sufficient enough to clarify the effectiveness and safety of TA. So, we carried out a meta-analysis of randomized controlled trials to investigate the efficacy and safety of the intravenous use of TA in TKA.
METHODSLiteratures were retrieved in Cochrane Library, OVID, PubMed, EMBASE, CNKI and Wanfang Data. All the related literatures were checked by two independent investigators and only the high quality randomized controlled trials were enrolled. Relevant data were analyzed using RevMan 5.1 to compare the difference of blood loss, transfusion and complications between TA group and control group.
RESULTSThere were 353 related literatures and only 22 randomized controlled trials met the inclusion criteria. The use of TA in TKA significantly reduced total blood loss by a mean of 435.41 ml (95% CI 300.62-570.21, P less than 0.01), post-operative blood loss by a mean of 406.69 ml (95% CI 333.16-480.22, P less than 0.01). TA also significantly lowered the transfusion rate (risk difference 0.30, 95% CI 0.21-0.39, P less than 0.01) and transfusion volume (mean difference 0.95 unit, 95% CI 0.53-1.37, P less than 0.01). The risks between TA group and control group in developing deep vein thrombosis and pulmonary embolism were not statistically significant.
CONCLUSIONTA is beneficial for patients undergoing TKA, which can significantly reduce total blood loss, postoperative blood loss, transfusion rate, and transfusion volume. Meanwhile TA is recommended to reduce deep vein thrombosis and pulmonary embolism following TKA.
Antifibrinolytic Agents ; therapeutic use ; Arthroplasty, Replacement, Knee ; Blood Loss, Surgical ; prevention & control ; Blood Transfusion ; Humans ; Postoperative Hemorrhage ; prevention & control ; Pulmonary Embolism ; chemically induced ; Randomized Controlled Trials as Topic ; Tranexamic Acid ; adverse effects ; therapeutic use ; Venous Thrombosis ; chemically induced